{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T17:33:26Z","timestamp":1783532006455,"version":"3.55.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>In this review, we discuss the most important aspects of the role of high-dose melphalan (HDM) and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Almost 40 years after the publication of the first study on safety and efficacy of HDM and ASCT in MM patients, and despite the introduction of several drugs and combinations with various targets on the plasma cell and the surrounding microenvironment, HDM\u2013ASCT still stands as a standard of care for the upfront treatment of newly diagnosed MM patients. Indeed, all attempts to replace HDM\u2013ASCT with novel-agent-based, non-transplant strategies have failed to demonstrate their efficacy, at least in terms of progression-free survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Despite such a long history in MM, a number of open issues regarding HDM\u2013ASCT still exist, from the choice between using transplant in first-line therapy or at relapse to the use of tandem HDM\u2013ASCT in high-risk patients. With the introduction of more and more effective multidrug regimens and of novel immunotherapeutic approaches, the challenge between transplant and non-transplant is not over yet.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000783","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:02:25Z","timestamp":1629666145000},"page":"642-647","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["The role of autologous stem-cell transplantation in multiple myeloma in 2021"],"prefix":"10.1097","volume":"33","author":[{"given":"Roberto","family":"Mina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"322","author":"Mcelwain","year":"1983","journal-title":"Lancet"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V70.3.869.869","article-title":"High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma","volume":"70","author":"Barlogie","year":"1987","journal-title":"Blood"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V89.3.789","article-title":"Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma","volume":"89","author":"Barlogie","year":"1997","journal-title":"Blood"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139014","article-title":"High-dose melphalan significantly increases mutational burden in multiple myeloma cells at relapse: results from a randomized study in multiple myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a mult","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-137575","article-title":"Upfront autologous hematopoietic stem-cell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly diagnosed multiple myeloma: long-term follow-up analysis of the randomized Phase 3 EMN02\/HO95 Study","volume":"136","author":"Cavo","year":"2020","journal-title":"Blood"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-136907","article-title":"Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized forte trial","volume":"136","author":"Gay","year":"2020","journal-title":"Blood"},{"key":"R18-20250526","first-page":"46","article-title":"Efficacy of carfilzomib-based induction\/consolidation with or without autologous transplant and lenalidomide or carfilzomib-lenalidomide maintenance in high-risk patients in the forte trial","volume":"5","author":"Mina","year":"2021","journal-title":"HemaSphere"},{"key":"R19-20250526","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"key":"R20-20250526","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8000","article-title":"Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM)","volume":"39","author":"Yong","year":"2021","journal-title":"J Clin Oncol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"R25-20250526","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123170","article-title":"Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-Krd consolidation in patients with newly diagnosed multiple myelo","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"R26-20250526","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: a clinical and correlative phase 2 study","volume":"134","author":"Landgren","year":"2019","journal-title":"Blood"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/leu.2016.381","article-title":"Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis","volume":"31","author":"Gay","year":"2017","journal-title":"Leukemia"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: Results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"key":"R29-20250526","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:08:49Z","timestamp":1748300929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000783","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}